1. Home
  2. QTWO vs GKOS Comparison

QTWO vs GKOS Comparison

Compare QTWO & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTWO
  • GKOS
  • Stock Information
  • Founded
  • QTWO 2004
  • GKOS 1998
  • Country
  • QTWO United States
  • GKOS United States
  • Employees
  • QTWO N/A
  • GKOS 995
  • Industry
  • QTWO Computer Software: Prepackaged Software
  • GKOS Medical/Dental Instruments
  • Sector
  • QTWO Technology
  • GKOS Health Care
  • Exchange
  • QTWO Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • QTWO 4.6B
  • GKOS 5.1B
  • IPO Year
  • QTWO 2014
  • GKOS 2015
  • Fundamental
  • Price
  • QTWO $74.96
  • GKOS $90.26
  • Analyst Decision
  • QTWO Buy
  • GKOS Strong Buy
  • Analyst Count
  • QTWO 16
  • GKOS 13
  • Target Price
  • QTWO $102.20
  • GKOS $155.00
  • AVG Volume (30 Days)
  • QTWO 764.0K
  • GKOS 1.0M
  • Earning Date
  • QTWO 04-30-2025
  • GKOS 04-30-2025
  • Dividend Yield
  • QTWO N/A
  • GKOS N/A
  • EPS Growth
  • QTWO N/A
  • GKOS N/A
  • EPS
  • QTWO N/A
  • GKOS N/A
  • Revenue
  • QTWO $696,464,000.00
  • GKOS $383,481,000.00
  • Revenue This Year
  • QTWO $13.64
  • GKOS $27.84
  • Revenue Next Year
  • QTWO $10.52
  • GKOS $27.99
  • P/E Ratio
  • QTWO N/A
  • GKOS N/A
  • Revenue Growth
  • QTWO 11.50
  • GKOS 21.85
  • 52 Week Low
  • QTWO $49.56
  • GKOS $77.91
  • 52 Week High
  • QTWO $112.82
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • QTWO 45.45
  • GKOS 41.57
  • Support Level
  • QTWO $73.72
  • GKOS $86.16
  • Resistance Level
  • QTWO $77.12
  • GKOS $94.55
  • Average True Range (ATR)
  • QTWO 4.25
  • GKOS 6.54
  • MACD
  • QTWO 0.30
  • GKOS 1.11
  • Stochastic Oscillator
  • QTWO 58.26
  • GKOS 54.51

About QTWO Q2 Holdings Inc.

Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: